Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Survodutide (BI 456906) is a GLP-1R/GCGR dual agonist developed by Boehringer Ingelheim, with outcomes of a phase 2 trial in MASLD and a phase 1 trial in cirrhosis published almost simultaneously with tirzepatide
As GLP1 receptor agonists capture public attention for much more than blood sugar control, clinicians are increasingly called upon to explain whats proven, whats experimental, and what remains unknown
Inquire with us today
2008 May;57(5):712-7
However, the review notes that these results, while promising, remain preliminary and require confirmation in larger outcome studies
US$ 23.17
US$ 27.88
US$ 29.01
US$ 24.60
US$ 21.64
US$ 23.95
